Supreme Pharmatech Accelerates Global Biosecurity Initiative through Advanced Molecular Bio-Scaffolding (MBS) Platform

On September 7, 2026, Supreme Pharmatech Co., Ltd. has officially expanded its core biotechnology portfolio into the veterinary medicine sector through the development of premium Molecular Bio-Scaffolding (MBS) platforms. Pioneered by international research and development divisions, this high-technology matrix enables the precise engineering of non-infectious structural protein shells that mirror target pathogens without utilizing live viral genomes. Establishing this clean-cell molecular platform eliminates the traditional biosecurity risks associated with conventional live-virus production channels. Proprietary manufacturing protocols ensure absolute batch structural fidelity, delivering highly stable antigenic raw materials engineered to meet strict international quality criteria.

This scalable bioprocessing architecture allows for the rapid adaptation of antigenic configurations to match real-time viral mutations and regional field strain dynamics. To demonstrate the real-world deployment of this technology, the corporate network plans to invest in a project consisting of a strategic Emergency Antigen Bank and an automated vaccine manufacturing line, boasting a capacity exceeding 100 million doses annually, at the premises of regional branch — Supreme Pharmatech Manufacturing in Azerbaijan. This advanced hub functions as the universal plug-and-play baseline to secure the livestock, poultry, and pet markets across the Caucasus region, serving as the primary operational blueprint before expanding this high-tech biosecurity model to other global territories.